Fos-Clin-Art

is a triple combination therapy for Plasmodium falciparum malaria

Under development by Deutsche Malaria GmbH (DMG), Hamburg, Germany

Fos-Clin-Art

Deutsche Malaria GmbH (DMG), jointly with Prof. Peter Kremsner’s team at the University of Tübingen, is developing a new combination therapy for Plasmodium falciparum malaria. The novel small-molecule treatment aims at improving the outcome of both severe and life-threatening malaria and of concomitant bacteriaemia through parenteral administration in children and adults.

DMG formerly “Jomaa Pharma GmbH” is a Hamburg-based company which was founded in 2003 and dedicated to the fight against malaria.

Its treatment consists of a synergistic, additive combination of three components: fosmidomycin, clindamycin and artesunate (together as triple combination “Fos-Clin-Arte”). Together, fosmidomycin and clindamycin cover the full spectrum of gram-negative and gram-positive bacteria. The three components possess excellent intrinsic antimalarial activity and have different modes of action against differing biochemical targets.

Since all three substances have a short half-life, the triple combination is expected to ameliorate and shorten the duration of the needed treatment.

The EUMF funding supports DMG’s efforts to conduct the clinical development of Fos-Clin-Art with an overall participant number of more than 5.000 patients in Africa, especially children with severe malaria.